Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit: Alexandra Glucksmann Invited to Highlight Company’s Progress in Applying Nanotechnology in the Life Sciences

Abstract:
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that Alexandra Glucksmann, Ph.D., the Company's Senior Vice President, Research and Business Operations, will present at the Nanotechnology Innovation Summit being organized by the Nano Science and Technology Institute (NSTI) in celebration of the 10th anniversary of the National Nanotechnology Initiative (NNI). The Summit is being held in Washington, D.C., from December 8-10, 2010.

Cerulean Pharma Inc. Senior Executive to Present at the National Nanotechnology Innovation Summit: Alexandra Glucksmann Invited to Highlight Company’s Progress in Applying Nanotechnology in the Life Sciences

Cambridge, MA | Posted on June 3rd, 2013

Dr. Glucksmann has been invited to give an address in the Innovations in Life Science Technologies session of the Summit. In her address, she will highlight Cerulean's advancement of first-in-class nanopharmaceutical drug candidates in pre-clinical and clinical development. Additionally, Dr. Glucksmann will showcase the unique potential of Cerulean's nanopharmaceutical platform to enhance efficacy of therapeutic agents while maintaining high quality of life for patients. Dr. Glucksmann will present at 11:10 a.m. EST on Friday, December 10, 2010 in the Gaylord National Hotel and Convention Center in Washington, D.C.

The Summit is gathering leaders in nanotechnology research and development as well as in policy and finance. Other invited speakers include representatives from the White House, federal government departments and agencies, academic institutes, and industry, who will discuss the latest developments and innovations in nanotechnology. The NNI was established in 2001 with the vision of advancing leadership in nanotechnology through collaborations and dedicated funding.

####

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Schwartz Communications
Andrew Law/Benjamin Navon
+1 781-684-0770

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Iranian Researchers Synthesize Stable Ceramic Nanopowders at Room Temperature September 20th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanomedicine

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

New non-invasive technique could revolutionize the imaging of metastatic cancer September 17th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

New star-shaped molecule breakthrough: Scientists at The University of Manchester have generated a new star-shaped molecule made up of interlocking rings, which is the most complex of its kind ever created September 22nd, 2014

Synthesis of Nanostructures with Controlled Shape, Size in Iran September 22nd, 2014

Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Events/Classes

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

IEEE International Electron Devices Meeting To Celebrate 60th Anniversary as The Leading Technical Conference for Advanced Semiconductor Devices September 18th, 2014

PEN Inc. Chairman, Scott Rickert, Will Webcast a Live Company Update September 25, 1 PM EDT September 17th, 2014

Dolomite to launch Meros TCU-100 temperature controller at Lab-on-a-Chip & Microarray World Congress September 15th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE